Drug guidance
Dexamethasone intravitreal implant for treating diabetic macular oedema, retinal vein occlusion and non-infectious uveitis
Condition
Eye
1 September 2023
Published on 01 Sep 2023
Last Updated on 01 Sep 2023
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended listing dexamethasone 0.7 mg intravitreal implant on the MOH List of Subsidised Drugs for treating diabetic macular oedema, macular oedema following retinal vein occlusion and non-infectious uveitis affecting the posterior segment of the eye. The decision was based on the unfavourable clinical and cost-effectiveness of intravitreal dexamethasone implant compared with current treatment options.